A61K 9 - Medicinal preparations characterised by special physical form

Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
11/2001
11/22/2001	US20010044472 Fluidizing agent, a binder compound, a starch, a disintegrant and a lubricant; free-flowing; tablets
11/22/2001	US20010044467 A prostaglandin applied topically to the clitoris
11/22/2001	US20010044466 Anticancer and antitumor agents
11/22/2001	US20010044460 Ophthalmic compositions for treating ocular hypertension
11/22/2001	US20010044423 Promoting vesical mucosa epithelium dilatation and/or healing vesical mucosa of a patient's bladder by administering to inside of bladder a solution of hyaluronic acid and/or a salt thereof
11/22/2001	US20010044421 Antimutagenic compositions for treatment and prevention of photodamage to skin
11/22/2001	US20010044419 Administering to skin a composition containing deoxyribonucleosides in concentrations sufficient to enhance DNA repair or reduce mutation frequency in a vehicle capable of delivering deoxyribonucleosides to skin cells
11/22/2001	US20010044409 Increase bioavailability of water insoluble drugs by spraying a surfactant-plasticizer/solubilizer solution on a drug-carrier mixture in a fluid bed granulator, and extruding, milling to a powdery mass of solid drug dispersion
11/22/2001	US20010044147 Delivery vehicles comprising stable lipid/nucleic acid complexes
11/22/2001	US20010044026 Placing a hog fuel mat including an ammonium chloride catalyst with flexible non-sticking layers on outside surfaces between screens in a preheated platen press and pressing the mat
11/22/2001	US20010043999 Polyvinyl alcohol and a setting system which may be hydrocolloids and cations; optionally sequestering agents; soft and hard capsules
11/22/2001	US20010043956 Hangover cure
11/22/2001	US20010043950 Core of fluvastatin, hydroxypropyl methyl cellulose and optionally other excipients, dosage form is color-stable during storage
11/22/2001	US20010043949 Biodegradable synthetic polymer microparticle, proteinaceous antigen and an enteric polymer which forms a coating layer on the surface of the microparticle; oral delivery of vaccine
11/22/2001	US20010043948 Lipid or other hydrophobic or amphiphilic compound is integrated into a polymeric matrix to alter drug release kinetics; drug released over longer periods of time by altering diffusion of water
11/22/2001	US20010043947 Soft chewable tablets
11/22/2001	US20010043946 Tablet form with more than 76% by weight of gabapentin; made by spray coating with binder solution and compressing into non-friable tablets; improved compressibility, compactibility
11/22/2001	US20010043945 In admixture with erodible matrix, for reliable controlled release of phenytoin sodium even after storage
11/22/2001	US20010043944 Pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system for the release of 17- beta -estradiol to the human organism
11/22/2001	US20010043943 Small intestine submucosa (SIS); controllably drawing fluid from the surrounding tissue and into an SIS layer placed on the wound, enhancing healing and restructuring properties of the SIS
11/22/2001	US20010043941 Such as delmopinol and octapinol for oral hygiene, comprising a solid edible chewable portion enclosing a reservoir portion having releasable unit dose, which is quickly released into the oral cavity upon chewing; can be for animals
11/22/2001	US20010043934 Formulations for amylin agonist peptides
11/22/2001	US20010043929 Enhanced circulation effector composition and method
11/22/2001	US20010043917 Bacteriophage modified by serial passageing or genetic engineering so the modified bacteriophage will remain active in the body for a longer time than the wild-type phage; infections
11/22/2001	US20010043914 In situ vaccination by administering to a tumor a slow-release microparticle containing Interferon-12; antigrowth, -tumor, -carcinogenic and -metastasis agents; with or without a synergistic cytokine
11/22/2001	US20010043908 Liquid oral compositions comprising a calcium compound and an acidulant
11/22/2001	US20010043906 Aerosolizing a solution of aqueous gamma-interferon, a stabilizer and a dispersant by forcing the solution through openings in a plate and delivering the droplets to a patient's respiratory tract; storage stability
11/22/2001	US20010043905 Method and compositions for detection and diagnosis of infectious diseases
11/22/2001	US20010042936 Process for producing solid creatine dosage forms and dosage forms obtainable thereby
11/22/2001	US20010042932 Process for preparing microparticles through phase inversion phenomena
11/22/2001	DE10033990A1 Cyclodextrine, die vorzugsweise an ihrer primären Fläche durch Säure- oder Aminfunktionen substituiert sind Cyclodextrins, which are preferably substituted on its primary surface by acid or amine functions
11/22/2001	DE10024396A1 Plaster composition for treating insect bites or nettle stings, based on menthol and ribwort tincture and colored to make it attractive to children
11/22/2001	DE10024154A1 Encapsulation of cells/substances uses an injection pump to form small spherical particles in an immobilizing mixture with external vibration on the pump and an electrical field at the hardening vessel
11/22/2001	DE10022095A1 Gel used e.g., in agriculture, health, nutrition and cosmetic products, comprising polyalpha-1,4-glucan, swelling agent and optionally starch
11/22/2001	DE10018221A1 Treating disorders of the teeth, gums or jawbones using growth hormones, preferably human growth hormone or dehydroepiandrosterone, useful e.g. for treating paradontosis or healing jaw operation wounds
11/22/2001	CA2409721A1 A coating composition for facilitating controlled release
11/22/2001	CA2409699A1 Novel polymorph v of torasemide
11/22/2001	CA2409506A1 Method for cell adhesion and wound healing
11/22/2001	CA2409437A1 Aldosterone antagonist composition for release during aldosterone acrophase
11/22/2001	CA2409005A1 Methods for decreasing cell proliferation based on (3r, 4r)-.delta.8-tetrahydrocannabinol-11-oic acids
11/22/2001	CA2408974A1 Cancer treatments by using a combination of an antibody against her2 and interleukin -2
11/22/2001	CA2408961A1 Use of ajulemic acid and related cannabinoids for the treatment of cancer
11/22/2001	CA2408870A1 Material based on biodegradable polymers and method for preparing same
11/22/2001	CA2408842A1 Method for treating retinal degeneration with purinergic receptor agonists
11/22/2001	CA2408689A1 Allantoin-containing skin cream
11/22/2001	CA2408383A1 Use of ellagic acid as anti-pollution cosmetic agent
11/22/2001	CA2408163A1 Methods for treatment of inflammatory diseases
11/22/2001	CA2407540A1 Propofol for treatment of sepsis
11/22/2001	CA2407254A1 Insulin formulation for inhalation
11/22/2001	CA2380423A1 Peptide pharmaceutical formulations
11/21/2001	EP1155701A1 Enteral sorbefacients
11/21/2001	EP1155697A1 Sustained release pharmaceutical composition containing glipizide and method for producing same
11/21/2001	EP1155692A1 Use of Paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby
11/21/2001	EP1155691A2 Anti-angiogenic compositions and methods of use
11/21/2001	EP1155690A2 Anti-angiogenic compositions and method of use
11/21/2001	EP1155689A2 Anti-angiogenic compositions and methods of use
11/21/2001	EP1155043A1 Stabilized cyclodextrin complexes
11/21/2001	EP1155021A1 Hesperitin pro-forms with enhanced bioavailability
11/21/2001	EP1154796A1 Novel albumin-free factor viii formulations
11/21/2001	EP1154793A1 Use of bioadhesives and adjuvants for the mucosal delivery of antigens
11/21/2001	EP1154786A2 Methods and compositions for altering mucus secretion
11/21/2001	EP1154778A2 Pharmaceutical preparation containing dithranol
11/21/2001	EP1154775A1 Therapeutic aqueous composition containing a hexahydro-5-pyrimidinamine compound and a polyalkoxylated fatty alcohol
11/21/2001	EP1154770A2 Premixed formulation of piperacillin sodium and tazobactam sodium injection
11/21/2001	EP1154765A1 Effervescent laxatives
11/21/2001	EP1154763A1 Patch for transdermal therapy
11/21/2001	EP1154762A1 Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
11/21/2001	EP1154761A1 Solid oral dosage form containing an enhancer
11/21/2001	EP1154760A1 Biodegradable composite material for the production of microcapsules
11/21/2001	EP1154759A1 Dispersible concentrate for the delivery of cyclosporin
11/21/2001	EP1154758A1 Controlled release formulation for treating copd
11/21/2001	EP1154757A1 Fast dispersing dosage forms free of gelatin
11/21/2001	EP1154756A2 Antibody fragment-targeted immunoliposomes for systemic gene delivery
11/21/2001	EP1154755A1 Liposome formulations
11/21/2001	EP1154734A1 Injectable collagen-based system for delivery of cells or therapeutic agents
11/21/2001	EP1106174A9 Compositions containing fat-soluble vitamins
11/21/2001	EP0998292B1 Method for inhibiting bone resorption
11/21/2001	EP0895473B1 Polysaccharide microspheres for the pulmonary delivery of drugs
11/21/2001	EP0874643B1 Bioresponsive pharmacologically-active polymers and articles made therefrom
11/21/2001	EP0852492B1 Transdermal matrix system
11/21/2001	EP0844870B1 Controlled release products
11/21/2001	EP0836645A4 Dry powder formulations of polynucleotide complexes
11/21/2001	EP0833667A4 Stabilization of polynucleotide complexes
11/21/2001	EP0802911B1 Hydrophobic taxane derivatives
11/21/2001	EP0722317B1 Liposomes containing particulate materials
11/21/2001	EP0706398B1 Pharmaceutical composition containing heparin, heparin fragments or their derivatives in combination with glycerol esters
11/21/2001	EP0643737B1 Conversion of powdered polymers
11/21/2001	CN1323348A Delivery system for porcine somatotropin
11/21/2001	CN1323344A DNA zyme and method for treating restenosis
11/21/2001	CN1323228A Methods instruments and materials for chondrocyte cell transplantation
11/21/2001	CN1323220A Insulin preparations for pulmonary delivery containing menthol
11/21/2001	CN1323219A Stable concentrated insulin preparations for pulmonary delivery
11/21/2001	CN1323210A Method for treating schizophrenia and means used in said method
11/21/2001	CN1323207A Use of ophthalmic composition comprising vitamin A and vitamin E
11/21/2001	CN1323206A Fumaric acid microtablets
11/21/2001	CN1323202A Sertraline oral concentrate
11/21/2001	CN1323201A Extended release buccal bioadhesive tablet
11/21/2001	CN1323200A New oral formulation for 5-HT4 agonists or antagonists
11/21/2001	CN1323199A Liposome-entrapped topoisomerase inhibitors
11/21/2001	CN1323198A Method for preparing a solution for nasal spray containing sex hormones and a cyclodextrin

1 ... 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 ... 2991